Company Encyclopedia
View More
name
YILING PHARMACEUTICAL
002603.SZ
Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for cardiovascular and cerebrovascular, respiratory, endocrine, neurological, digestive, immune, and urinary diseases, diabetes mellitus, oncology, sleep-improving, and anti-aging. The company also provides dietary supplements, disinfection products, personal protective equipment, as well as formula granules.
3.157 T
002603.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking181/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE-2.51%D
    • Profit Margin-4.64%D
    • Gross Margin63.91%A
  • Growth ScoreE
    • Revenue YoY-25.83%E
    • Net Profit YoY-287.84%E
    • Total Assets YoY-14.41%E
    • Net Assets YoY-6.86%D
  • Cash ScoreE
    • Cash Flow Margin-2156.74%E
    • OCF YoY-25.83%E
  • Operating ScoreC
    • Turnover0.39C
  • Debt ScoreB
    • Gearing Ratio24.77%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules

    Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules

    marketscreener·
    SZ
    002603
    +0.06%
    marketscreener·
    SZ
    002603
    +0.06%

    Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material

    Yiling Pharmaceutical Unit Gets China Nod for Alzheimer's Drug Raw Material

    marketscreener·
    SZ
    002603
    +0.06%
    marketscreener·
    SZ
    002603
    +0.06%

    The morning session of the 2025 National Conference opens: CR Sanjiu and YILING PHARMACEUTICAL enter the arena, negotiations on traditional Chinese medicine varieties begin

    According to reporters from the on-site negotiations for the 2025 National Medical Insurance Directory and the price negotiations for innovative drugs with commercial insurance, the process for the fourth day of the 2025 national negotiations began around 8 a.m. Representatives from pharmaceutical companies such as CR Sanjiu, Jianmin Pharmaceutical, Beijing YILING PHARMACEUTICAL, Eisai, and Kereis Pharmaceuticals entered the venue in succession to await negotiations. Representatives from traditional Chinese medicine companies entered in large numbers, and negotiations for traditional Chinese medicine varieties are expected to begin

    Zhitong·
    SZ
    002603
    +0.06%
    SZ
    000999
    +0.21%
    Zhitong·
    SZ
    002603
    +0.06%
    SZ
    000999
    +0.21%

    Zhejiang Merchants Securities: Upgrades YILING PHARMACEUTICAL to "Buy" rating, with future performance expected to continue improving

    Zhejiang Merchants Securities raised the rating of YILING PHARMACEUTICAL to "Buy," expecting future performance to continue to improve. The company achieved a net profit attributable to shareholders of 1 billion yuan in the first three quarters, with a net profit of 332 million yuan in Q3, slightly exceeding expectations. It is anticipated that the gross profit margin will improve by 2026 due to the decline in the prices of traditional Chinese medicinal materials and the recovery of product gross profit margins, with net profit growth expected to surpass revenue growth. Considering the normalization of channel inventory, future performance is expected to grow steadily

    Zhitong·
    SZ
    002603
    +0.06%
    Zhitong·
    SZ
    002603
    +0.06%

    YILING PHARMACEUTICAL: Wholly-owned subsidiary Anastrozole raw material drug has received the approval notice for listing application

    YILING PHARMACEUTICAL's wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received the notice of approval for the marketing application of anastrozole chemical raw materials from the National Medical Products Administration. Anastrozole is used to treat estrogen-related tumors, particularly in postmenopausal hormone receptor-positive female breast cancer patients. Another wholly-owned subsidiary of YILING PHARMACEUTICAL holds the approval for anastrozole tablet formulation, and integrated production of raw materials and formulations is expected to be achieved this year

    Zhitong·
    SZ
    002603
    +0.06%
    Zhitong·
    SZ
    002603
    +0.06%
    © 2025 Longbridge｜Disclaimer